You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 25, 2024

Litigation Details for Novartis Pharmaceuticals Corporation v. Alembic Pharmaceuticals Limited (D. Del. 2019)

✉ Email this page to a colleague

« Back to Dashboard

Novartis Pharmaceuticals Corporation v. Alembic Pharmaceuticals Limited (D. Del. 2019)

Docket	⤷ Sign Up	Date Filed	2019-10-24
Court	District Court, D. Delaware	Date Terminated	2024-02-07
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	8,101,659; 8,796,331; 8,877,938; 9,388,134
Link to Docket	External link to docket

Small Molecule Drugs cited in Novartis Pharmaceuticals Corporation v. Alembic Pharmaceuticals Limited

The small molecule drugs covered by the patents cited in this case are ⤷ Sign Up and ⤷ Sign Up .

Details for Novartis Pharmaceuticals Corporation v. Alembic Pharmaceuticals Limited (D. Del. 2019)

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign Up
Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2020-01-06	14	Answer to Complaint	United States Patent Nos. 8,101,659 (the “’659 patent”), 8,796,331 (the “’331 patent”), and 8,877,938…103 mg, prior to the expiration of U.S. Patents Nos. 8,101,659 (the Case 1:19-cv-02021-LPS Document…and every asserted claim of United States Patent No. 8,101,659 is invalid for failing to satisfy one or… and enforceable asserted claim of U.S. Patent No. 8,101,659. …entered that each claim of United States Patent Nos. 8,101,659, 8,796,331, and 8,877,938 is invalid;	External link to document
2022-08-26	196	~Util - Set Hearings AND Order	validity of U.S. Patent Nos. 8,101,659 (the 659 patent) and 8,796,331 (the 331 patent) is scheduled for…validity of U.S. Patent Nos. 8,877,938 (the 938 patent) and 9,388,134 (the 134 patent) is scheduled for…2019 7 February 2024 1:19-cv-02021 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2022-11-04	226	Stipulation-General (See Motion List for Stipulation to Extend Time)	Order Regarding Post-Trial Briefing for U.S. Patent No. 8,796,331 by Novartis Pharmaceuticals Corporation.…2019 7 February 2024 1:19-cv-02021 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2022-11-04	227	Order	Order Regarding Post-Trial Briefing for U.S. Patent No. 8,796,331. Signed by Judge Richard G. Andrews on 11…2019 7 February 2024 1:19-cv-02021 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2023-07-07	239	Opinion	infringement of U.S. Patent 8,877,938 (the “’938 Patent”), 9,388,134 (the “’134 Patent”), 8,101,659 (the “’659 …659 Patent”) and 8,796,331 (the “’331 Patent”). Only the ’659 Patent is at issue in this opinion. The parties… of that patent. (/d.). I held separate trials addressing the ’938 Patent and the ’134 Patent. (D.I. 604…Ciba-Geigy, was issued U.S. Patent No. 5,399,578 (“the 578 Patent”). (JTX-23). That patent disclosed and claimed…the °659 Patent claims are obvious over EP ’072, the ’996 Patent/Ksander, and the ’578 Patent/Diovan®	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.